DiaMedica Therapeutics Inc. (NASDAQ:DMAC – Get Free Report) major shareholder Koch Thomas Von bought 1,200,000 shares of the company’s stock in a transaction dated Friday, June 28th. The stock was purchased at an average price of $2.50 per share, with a total value of $3,000,000.00. Following the completion of the transaction, the insider now directly owns 5,526,435 shares in the company, valued at approximately $13,816,087.50. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.
DiaMedica Therapeutics Price Performance
DMAC stock remained flat at $2.95 during trading on Monday. 236,702 shares of the company were exchanged, compared to its average volume of 48,892. DiaMedica Therapeutics Inc. has a twelve month low of $1.94 and a twelve month high of $4.45. The business’s fifty day moving average is $2.77 and its 200-day moving average is $2.82. The company has a market capitalization of $111.99 million, a P/E ratio of -4.82 and a beta of 1.74.
DiaMedica Therapeutics (NASDAQ:DMAC – Get Free Report) last announced its quarterly earnings results on Wednesday, May 8th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.02. As a group, research analysts forecast that DiaMedica Therapeutics Inc. will post -0.67 earnings per share for the current fiscal year.
Hedge Funds Weigh In On DiaMedica Therapeutics
Analyst Ratings Changes
A number of equities analysts recently issued reports on DMAC shares. Craig Hallum started coverage on shares of DiaMedica Therapeutics in a research report on Wednesday, April 24th. They set a “buy” rating and a $8.00 price objective for the company. Oppenheimer reiterated an “outperform” rating and set a $6.00 price objective (down from $7.00) on shares of DiaMedica Therapeutics in a research report on Thursday, March 21st.
Check Out Our Latest Stock Report on DiaMedica Therapeutics
DiaMedica Therapeutics Company Profile
DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.
Featured Stories
- Five stocks we like better than DiaMedica Therapeutics
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- These Top 3 Banks Raise Dividends After Passing Fed Stress Test
- Financial Services Stocks Investing
- Hitch a Ride with Lyft Stock for Double-Digit Gains in 2nd Half
- Investing in Travel Stocks Benefits
- Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Receive News & Ratings for DiaMedica Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DiaMedica Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.